Evofem Partners With Windtree Therapeutics to Slash PHEXXI Manufacturing Costs By 55%-60% Through New License And Supply Agreement; There Will Be No Cost To Evofem For The Tech Transfer To The New Manufacturer Engaged By Windtree.

Author: Benzinga Newsdesk | March 26, 2025 08:49am

Evofem's Cost to Manufacture PHEXXI will Decrease by 55% - 60% --

SAN DIEGO, March 26, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB:EVFM) (Evofem or the Company) today announced that it has entered into a License and Supply Agreement (L&S Agreement) with Windtree Therapeutics, Inc. (NasdaqCM: WINT), under which Windtree will be Evofem's sourcing partner for PHEXXI® (lactic acid, citric acid and potassium bitartrate). This FDA-approved hormone-free contraceptive vaginal gel is applied 0 to 60 minutes before each act of intercourse. It prevents pregnancy by maintaining the normal vaginal biome which has a slightly acidic pH that is inhospitable to sperm.

Under the L&S Agreement, Windtree will leverage its manufacturing contacts to reduce the cost to manufacture PHEXXI. Evofem expects PHEXXI COGS will decrease by 55% to 60% from current levels. Furthermore, there will be no cost to Evofem for the tech transfer to the new manufacturer engaged by Windtree.  

Posted In: EVFM WINT